Department of Gastroenterology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York.
Macmillan GP Cancer and End of Life lead, Vale of York Clinical Commissioning Group, West Offices Station Rise, York.
Br J Gen Pract. 2021 Jul 29;71(709):e643-e651. doi: 10.3399/BJGP.2020.1098. Print 2021 Aug.
The faecal immunochemical test (FIT) is now available to support clinicians in the assessment of patients at low risk of colorectal cancer (CRC) and within the bowel cancer screening programme.
To determine the diagnostic accuracy of FIT for CRC and clinically significant disease in patients referred as they were judged by their GP to fulfil National Institute for Health and Care Excellence guideline 12 (NG12) criteria for suspected CRC.
Patients referred from primary care with suspected CRC, meeting NG12 criteria, to 12 secondary care providers in Yorkshire and Humber were asked to complete a FIT before investigation.
The diagnostic accuracy of FIT based on final diagnosis was evaluated using receiver operating characteristics analysis. This permitted a statistically optimal cut-off value for FIT to be determined based on the maximisation of sensitivity and specificity. Clinicians and patients were blinded to the FIT results.
In total, 5040 patients were fully evaluated and CRC was detected in 151 (3.0%). An optimal cut-off value of 19 µg Hb/g faeces for CRC was determined, giving a sensitivity of 85.4% (95% confidence interval [CI] = 78.8% to 90.6%) and specificity of 85.2% (95% CI = 84.1% to 86.2%). The negative predictive value at this cut-off value was 99.5% (95% CI = 99.2% to 99.7%) and the positive predictive value 15.1% (95% CI = 12.8% to 17.7%). Sensitivity and specificity of FIT for CRC and significant premalignant polyps at this cut-off value were 62.9% (95% CI = 57.5% to 68.0%) and 86.4% (95% CI = 85.4% to 87.4%), respectively; and when including all organic enteric disease were 35.7% (95% CI = 32.9% to 38.5%) and 88.6% (95% CI = 87.5% to 89.6%), respectively.
FIT used in patients fulfilling NG12 criteria should allow for a more personalised CRC risk assessment. FIT should permit effective, patient-centred decision-making to inform the need for, type, and timing of further investigation.
粪便免疫化学测试(FIT)现在可用于支持临床医生评估结直肠癌(CRC)风险较低的患者,以及在结直肠癌筛查计划中。
确定 FIT 在符合国家卫生与保健卓越研究所(NICE)指南 12(NG12)标准的疑似 CRC 患者中的诊断准确性。
从初级保健机构转介疑似 CRC 并符合 NG12 标准的患者,被要求在调查前完成 FIT。
使用受试者工作特征(ROC)分析评估基于最终诊断的 FIT 诊断准确性。这允许根据敏感性和特异性的最大化确定 FIT 的统计学最佳截断值。临床医生和患者对 FIT 结果不知情。
共评估了 5040 例患者,其中 151 例(3.0%)检测出 CRC。确定了用于 CRC 的最佳截断值为 19 µg Hb/g 粪便,其敏感性为 85.4%(95%置信区间[CI] = 78.8%至 90.6%),特异性为 85.2%(95% CI = 84.1%至 86.2%)。在此截断值下,阴性预测值为 99.5%(95% CI = 99.2%至 99.7%),阳性预测值为 15.1%(95% CI = 12.8%至 17.7%)。在该截断值下,FIT 对 CRC 和显著癌前息肉的敏感性和特异性分别为 62.9%(95% CI = 57.5%至 68.0%)和 86.4%(95% CI = 85.4%至 87.4%);包括所有有机肠道疾病时,敏感性和特异性分别为 35.7%(95% CI = 32.9%至 38.5%)和 88.6%(95% CI = 87.5%至 89.6%)。
在符合 NG12 标准的患者中使用 FIT 应该可以进行更个性化的 CRC 风险评估。FIT 应允许进行有效的、以患者为中心的决策,以告知进一步检查的必要性、类型和时间。